High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Jersey Mike’s Subs, with its 5.96% stock-price decline Thursday, is hardly alone in having a first-day share slide. This year, shares for hedge fund Pershing Square, nuclear fuel company Standard Nuclear and biotech firm Generate Biomedicines fell 18%, 18% and 21% respectively on their first trading days, according to Dealogic.
Ark Invest's top investor is adding to stocks that went public over the past year.
Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 14, Morgan Stanley increased its price objective on Generate Biomedicines, Inc. (NASDAQ:GENB) to $22 from $20. The firm maintained an “Overweight” rating on the shares. Separately, Generate Biomedicines, Inc. (NASDAQ:GENB)’s GB-0895 (anti-TSLP) program […]
Recent trading snapshot and business context Generate Biomedicines (GENB) has drawn investor interest after a mixed stretch in the stock, with a small gain of 0.2% over the past day set against a decline of 9.7% over the past week. Over the past month the stock is roughly flat, while the past 3 months show a gain of 10.0%. This recent trading context sits alongside a market value of about US$1.68b and a share price of US$13.12 at the last close. See our latest analysis for Generate...
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
Nvidia’s backing highlights growing confidence in AI-powered biotech stocks.
Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the best low priced biotech stocks to invest in. On April 13, H.C. Wainwright initiated coverage of Generate Biomedicines, Inc. (NASDAQ:GENB) with a Buy rating, setting a $16 price target. The firm told investors in a research note that the stock has fallen over 20% even as GB-0895 advanced into […]
Generate Biomedicines: Recent Trading Moves And Core Business Snapshot Generate Biomedicines (GENB) has seen recent share price pressure, with a 10% decline over the past week and a similar move over the past month, bringing the latest close to US$11.21. For context, the company reports revenue of US$31.893 million alongside a net loss of US$249.523 million, reflecting the costs of developing its generative biology platform and early stage pipeline of protein based therapeutics. See our...
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
